Ratings AMN Healthcare Services, Inc.

Equities

AMN

US0017441017

Market Closed - Nyse Other stock markets 04:00:02 2024-04-22 pm EDT			5-day change	1st Jan Change
56.51 ^USD	-0.77%		-1.02%	-24.53%

Apr. 22	Truist Lowers Price Target on AMN Healthcare Services to $70 From $88, Keeps Buy Rating	MT
Feb. 28	Amn Healthcare Services Insider Bought Shares Worth $991,906, According to a Recent SEC Filing	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

The company has a low valuation given the cash flows generated by its activity.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
With an expected P/E ratio at 33.12 and 21.84 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
AMN HEALTHCARE SERVICES, INC.	-24.53%	2.14B		A-
CVS HEALTH CORPORATION	-11.82%	87.77B		B-
HCA HEALTHCARE, INC.	+14.64%	82.08B		C+
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+13.31%	30.03B		C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-10.66%	17.08B		B
QUEST DIAGNOSTICS INCORPORATED	-5.65%	14.45B		A-
EUROFINS SCIENTIFIC SE	+4.41%	12.37B		A-
PURE HEALTH HOLDING	-31.05%	11.89B	-	-
FRESENIUS MEDICAL CARE AG	+4.43%	12.17B		A-
DAVITA INC.	+26.50%	11.62B		B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes